| Drug Name |
Tigecycline |
| Drug ID |
BADD_D02217 |
| Description |
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005. |
| Indications and Usage |
For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes and Bacteroides fragilis. Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros. |
| Marketing Status |
approved |
| ATC Code |
J01AA12 |
| DrugBank ID |
DB00560
|
| KEGG ID |
D01079
|
| MeSH ID |
D000078304
|
| PubChem ID |
54686904
|
| TTD Drug ID |
D0G4OD
|
| NDC Product Code |
67680-002; 63323-960; 70121-1647; 71288-019; 55150-228; 0781-3481; 0008-4990; 58623-0048; 63415-0134; 68225-013; 60505-6098; 60715-1001; 16729-364; 0008-4994; 70600-002; 44657-0055 |
| UNII |
70JE2N95KR
|
| Synonyms |
Tigecycline | TBG-MINO | 9-(tert-Butylglycylamido)minocycline | Tygacil | GAR 936 | GAR-936 | GAR936 |
